1755-P: Improved Glycemic Control with Insulin Glargine 300 U/ml in Insulin-Naïve Chinese People with T2D Uncontrolled on GLP-1RAs: A Real-World Retrospective Cohort Study
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-1755-p ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von LIJUN DUAN und 12 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction and Objective: Real-world data on the effectiveness and safety of second-generation basal insulin (BI) in insulin-naïve Chinese people with T2D uncontrolled with GLP-1 RAs are limited.
Methods
IMPROVE G was a retrospective, single-arm, cohort study using data from the Tianjin regional electronic medical records database in northern China. Adult people with T2D uncontrolled with a GLP-1 RA (HbA1c 7-18%) who initiated Gla-300 between Jan 2021 and Dec 2024 were assessed (n=240), including people who added Gla-300 to GLP-1 RA (add-on BI) and those who switched to Gla-300. Mean changes from baseline in HbA1c, FPG, body weight, insulin dose, target achievement and hypoglycemia rates at 6 and 12 months were assessed. Subgroup analyses were conducted based on treatment regimen.
Results
HbA1c and FPG significantly decreased by 0.98% and 2.05 mmol/L, respectively, at 6 months (both p<0.001). At 6 months, 35.4% of people achieved HbA1c <7%. Compared with baseline, no significant change in body weight was observed and there were significantly fewer hypoglycemia events. Gla-300 showed significant glycemic improvements across both subgroups at 6 months, with this effect maintained at 12 months.
Conclusion
Gla-300 improved glycemic control with no body weight gain or no increase in hypoglycemia risk in Chinese people with insulin-naïve T2D uncontrolled with GLP-1 RAs in a real-world setting. Disclosure L. Duan: None. Y. Gong: None. G. Liu: None. H. Zhao: None. Z. Meng: None. J. Tong: None. S. Jiang: None. J. Cao: None. C. Xu: None. W. Liu: Employee; Current; Sanofi. Q. Du: Employee; Current; Sanofi China. L. Kang: Employee; Current; Sanofi China. M. Zhang: Employee; Current; Sanofi China. Funding This study was funded by Sanofi. Professional medical writing support was provided by Simone Tait, CMPP, of Springer Health+, and was funded by Sanofi.
Zitieren
APA
DUAN, L., GONG, Y., LIU, G., ZHAO, H., MENG, Z., TONG, J., JIANG, S., CAO, J., XU, C., LIU, W., DU, Q., KANG, L., & ZHANG, M. (2026). 1755-P: Improved Glycemic Control with Insulin Glargine 300 U/ml in Insulin-Naïve Chinese People with T2D Uncontrolled on GLP-1RAs: A Real-World Retrospective Cohort Study. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1755-p
Vancouver
DUAN L, GONG Y, LIU G, ZHAO H, MENG Z, TONG J, et al. 1755-P: Improved Glycemic Control with Insulin Glargine 300 U/ml in Insulin-Naïve Chinese People with T2D Uncontrolled on GLP-1RAs: A Real-World Retrospective Cohort Study. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1755-p
BibTeX
@article{DUAN2026,
author = {DUAN, LIJUN and GONG, YIHUI and LIU, GUANYING and ZHAO, HEJUN and MENG, ZHENXING and TONG, JINGKAI and JIANG, SHAN and CAO, JING and XU, CHAOFEI and LIU, WEIWEI and DU, QIN and KANG, LEI and ZHANG, MINLU},
title = {1755-P: Improved Glycemic Control with Insulin Glargine 300 U/ml in Insulin-Naïve Chinese People with T2D Uncontrolled on GLP-1RAs: A Real-World Retrospective Cohort Study},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-1755-p}
}
EUVIMED